Search

Your search keyword '"Yun, Tak"' showing total 349 results

Search Constraints

Start Over You searched for: Author "Yun, Tak" Remove constraint Author: "Yun, Tak"
349 results on '"Yun, Tak"'

Search Results

1. Fractonic Quantum Quench in Dipole-constrained Bosons

2. Unveiling UV/IR Mixing via Symmetry Defects: A View from Topological Entanglement Entropy

3. A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma.

5. Aspects of $\mathbb{Z}_N$ rank-2 gauge theory in $(2+1)$ dimensions: construction schemes, holonomies, and sublattice one-form symmetries

6. Effective Field Theory of Dipolar Braiding Statistics in Two Dimensions

7. Hybrid rank-1 and rank-2 U(1) lattice gauge theory, the F3 model, and its effective field theory

8. Rank-2 Toric Code in Two Dimensions

10. Dual topological nodal line and nonsymmorphic Dirac semimetal in three dimensions

12. Ferromagnetic nodal-line metal in monolayer {\em h}-InC

13. Proposal of a spin-one chain model with competing dimer and trimer interactions

14. Resonating Valence Bond States with Trimer Motifs

15. Analysis of Response and Progression Patterns of Tyrosine Kinase Inhibitors in Recurrent or Metastatic Adenoid Cystic Carcinoma: A Post Hoc Analysis of Two KCSG Phase II Trials

16. Type-II Weyl cone transitions in driven semimetals

17. Adiabatic Green's function technique and the transient behavior in time-dependent fermion-boson coupled models

18. Dynamics of magnon fluid in Dzyaloshinskii-Moriya magnet and its manifestation in magnon-Skyrmion scattering

20. Fate of Topology in Spin-1 Spinor Bose-Einstein Condensate

21. Table S1 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

22. Figure S4 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

23. Supplementary Material 1 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

24. Data from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

25. Artificial intelligence‐powered spatial analysis of tumor‐infiltrating lymphocytes as a predictive biomarker for axitinib in adenoid cystic carcinoma

27. Spatial ecology of little egret (Egretta garzetta) in Hong Kong uncovers preference for commercial fishponds

28. A Phase 2 Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

29. Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial.

34. Aspects of $\mathbb{Z}_N$ rank-2 gauge theory in $(2+1)D$: construction schemes, holonomies, and sublattice one-form symmetries

36. A prospective phase II trial of pembrolizumab plus lenvatinib in advanced adrenal cortical carcinoma after failure of platinum- and mitotane-based chemotherapy (ACCOMPLISH).

46. A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17–11)

48. Effective Field Theory of Dipolar Braiding Statistics in Two Dimensions

50. Rank-2 toric code in two dimensions

Catalog

Books, media, physical & digital resources